VEGF-A as an inhibitor of angiogenesis and methods of using same
US7553496B2 · kind B2 · utility
30Cited by
4References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 21, 2004 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Aug 25, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization associated with neovascular disease. Administration of vascular endothelial growth factor (VEGF)-A into the eye when macrophage infiltration is reduced inhibits ocular angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.